Skip to main content
ELUT
NASDAQ Life Sciences

Elutia Faces Nasdaq Delisting, Secures $15M Loan, and Divests SimpliDerm

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.941
Mkt Cap
$41.6M
52W Low
$0.5
52W High
$2.5
52W Position info
88% above low
Off High info
62% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ELUT sits 88% above its 52-week low of $0.5.

Summary

Elutia faces Nasdaq delisting, secures a $15M loan with warrants, and divests SimpliDerm for up to $11M amid continued losses.


Key Events · Legal and Risk Events · ELUT

  • Nasdaq Delisting Notice

    Received August 6, 2026, for stock price below $1.00 for 30 consecutive days. Compliance deadline is February 2, 2027.

  • $15M Loan Secured

    Senior secured term loan from Avenue Capital Group: $10M funded, $5M delayed draw. Includes warrants for 1,395,348 shares at $0.86.

  • SimpliDerm Divestiture

    Agreement to sell SimpliDerm business for up to $11M: $8M base, $2M milestone, $1M earn-out.

  • Q2 Financials

    Net loss of $7.6M, cash of $19.9M. Company states funding sufficient through NXT-41x launch.


Analysis · ELUT · Life Sciences

A Nasdaq delisting notice landed on August 6, 2026, after the stock traded below $1.00 for 30 consecutive business days, giving the company until February 2, 2027, to regain compliance. To shore up liquidity, a $15 million senior secured term loan was secured from Avenue Capital Group, with $10 million funded immediately and $5 million available as a delayed draw. The loan includes warrants exercisable for 1,395,348 shares at $0.86 per share, adding potential dilution. Additionally, an agreement to sell the SimpliDerm business for up to $11 million will streamline operations but also removes a significant revenue source. The company reported a Q2 net loss of $7.6 million and cash of $19.9 million, indicating ongoing financial challenges.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ELUT was trading at $0.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41.6M. The 52-week trading range was $0.50 to $2.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELUT - Latest Insights

ELUT
Nov 05, 2026, 4:17 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7509
Real-time Price: $0.810 info
Change: +$0.0591 (+8%) info
Market Cap: $35.874M info
ELUT
Nov 05, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.7509
Real-time Price: $0.810 info
Change: +$0.0591 (+8%) info
Market Cap: $35.874M info
ELUT
Aug 21, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9509
Real-time Price: $0.810 info
Change: -$0.1409 (-15%) info
Market Cap: $35.874M info
ELUT
Aug 13, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.871701
Real-time Price: $0.810 info
Change: -$0.061701 (-7%) info
Market Cap: $35.874M info
ELUT
Aug 13, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7914
Real-time Price: $0.810 info
Change: +$0.0186 (+2%) info
Market Cap: $35.874M info